JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil

Condition(s) studied

Investigational drug(s) / intervention(s)

Topical Minoxidil 5% Solution: Topical minoxidil 5% solution applied to the affected scalp areas for 12 weeks. Men will apply 1 cc twice daily and women will apply 1 cc once daily.

Scalp Punch Biopsy: Three 2 mm punch biopsies will be obtained during the study: one from the balding scalp area and one from the non-balding scalp area at baseline, and one from the balding scalp area after 12 weeks of treatment.

Tissue JAK2 Protein Measurement by ELISA: Tissue samples obtained from scalp punch biopsies will be analyzed for Janus Kinase 2 (JAK2) protein levels using ELISA at baseline and after 12 weeks of treatment.

Study summary

Androgenetic alopecia is a common form of progressive hair loss. This prospective single-arm pre-post interventional study aims to assess tissue Janus Kinase 2 (JAK2) expression in patients with androgenetic alopecia by comparing balding and non-balding scalp at baseline, and to evaluate changes in JAK2 expression in balding scalp after 3 months of topical minoxidil 5% therapy. Clinical response will be assessed using standardized trichoscopic parameters.

Eligibility

Primary outcome measure(s)

• Baseline Difference in Tissue JAK2 Protein Levels Between Balding and Non-Balding Scalp — Baseline
  Comparison of tissue Janus Kinase 2 (JAK2) protein levels measured by ELISA in scalp biopsy specimens obtained at baseline from the balding area (vertex) and the non-balding area (occipital scalp) of participants with androgenetic alopecia.

Trial sites (1)

More Kasr El Aini Hospital trials in Egypt

Other trials for the same condition